The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
Fcked. Just like Vela.
How can we go to the meetings if they’re not held online ? 🤔 It’s a long way to go to Cottingley from down South!
Not Ebitda positive anytime soon.
GDR have got more shares than Cambridge Nutritional Sciences (previously ODX) 🤦♂️
Only if there’s substantial profits and a share buyback.
Might not see a spike at this rate….
That’s if it’s rectifiable!
Is much needed to rectify the situation.
Just hit an annual low.
Hardly confidence inspiring is it ??
JN’s performance has been 💩 of late.
💤
If you don’t perform you’re OUT.
Why should it be different at Vela Technologies ? 🤔
Bill is just a cowboy. Yeehah
Let’s make this easy - I won’t be accepting anything less than 10p.
I’d take 10p and RUN.
What excuse the BoD make in the next quarterly update!
“My suspicion is that long term they are trying to keep the price down because this will go private and list on the NASDAQ at a much higher price.”
So what price do you think CIZ investors will want ?
CIZ is 💤
CDT -
“On May 28, 2024, Conduit Pharmaceuticals Inc. (the "Company”) received a notice (the "Notice”) it was expecting from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq”) notifying the Company that, due to the previously disclosed resignation of Ms. Jennifer McNealey from the Company’s Board of Directors (the "Board”) and from all committees on which she served, the Company, effective as of such date of resignation, was not in compliance with Nasdaq’s independent audit committee requirements as set forth in Listing Rule 5605 as a result of the audit committee being comprised of only two independent directors.
The Company has until the earlier of its next annual shareholders’ meeting, or May 13, 2025 or, if the next annual shareholders’ meeting is held before November 12, 2024, then the Company must evidence compliance no later than November 12, 2024. The Notice has no immediate effect on the listing of the Company’s securities on Nasdaq.
The Company intends to regain compliance with the requirement that the audit committee be comprised of at least three independent directors prior to the expiration of the cure period provided pursuant to Nasdaq Listing Rule 5605(c)(4).”
And look where the SP is sat at.